查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1737151

全球纖維蛋白原濃縮物市場規模（依產品、應用、區域範圍、預測）

Global Fibrinogen Concentrates Market Size By Product (Animal Fibrinogen Concentrates, Human Fibrinogen Concentrate), By Application (Congenital Fibrinogen Deficiency, Surgical Procedures), By Geographic Scope And Forecast
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

纖維蛋白原濃縮物市場規模與預測

2024 年纖維蛋白原濃縮物市場規模價值 31.1 億美元，預計到 2032 年將達到 46.3 億美元，2026 年至 2032 年的複合年成長率為 5.64%。

由於血液相關疾病在人群中的盛行率不斷上升，以及人們對纖維蛋白原濃縮物的接受度不斷提高，預計纖維蛋白原濃縮物市場將顯著成長。全球纖維蛋白原濃縮物市場報告對市場進行了全面評估，全面分析了關鍵細分市場、趨勢、市場促進因素、限制因素、競爭格局以及影響市場的關鍵因素。

定義全球纖維蛋白原濃縮物市場

纖維蛋白原是一種存在於血漿中的糖蛋白，由肝臟產生。纖維蛋白原存在於脊椎動物體內，有助於血塊的形成。但纖維蛋白原含量低會導致血管內形成血塊，進而引發血栓症，阻礙血液在循環系統中的正常流動。纖維蛋白原會降低血液中的纖維蛋白原濃度，進而導致血塊的形成。血栓症是一種罕見的出血性疾病，其特徵為輕度至嚴重出血。纖維蛋白原缺乏症有三種：低纖維蛋白原血症、無纖維蛋白原血症、纖維蛋白原缺乏症。如果患者大量出血，纖維蛋白原濃度會增加整個血塊的硬度，減少術後輸血需求。

全球纖維蛋白原濃縮物市場概況

在這個競爭激烈的世界，由於生活方式的改變，人們的壓力不斷增加，導致血液相關疾病的發生率上升。據估計，先天性纖維蛋白原在該市場中佔據最大佔有率，這有助於降低血友病的發生率，並催生出更優質的纖維蛋白原產品。纖維蛋白原濃縮物在先天性纖維蛋白原缺乏症等出血相關疾病患者中的使用日益增多，是推動該市場成長的主要因素。如今，人們的健康意識日益增強，將健康放在首位也是推動該市場成長的關鍵因素。

目前，纖維蛋白原濃縮物正被個人和企業廣泛接受，以取代傳統的纖維蛋白原來源，包括冷凍血漿和冷沉澱。由於患者人數的增加以及各種外科手術的使用導致對纖維蛋白原的需求增加，纖維蛋白原濃縮物市場正在成長。此外，纖維蛋白原濃縮物也用於製備抗凝血劑，用於治療先天性無纖維蛋白原血症、纖維蛋白原血症、低纖維蛋白原血症等。

目錄

第1章全球纖維蛋白原濃縮物市場簡介

  • 市場概覽
  • 研究範圍
  • 先決條件

第2章執行摘要

第3章：已驗證的市場研究調查方法

  • 資料探勘
  • 驗證
  • 第一手資料
  • 資料來源列表

4. 纖維蛋白原濃縮物的全球市場展望

  • 概述
  • 市場動態
    • 驅動程式
    • 限制因素
    • 機會
  • 波特五力模型
  • 價值鏈分析

5. 全球纖維蛋白原濃縮物市場（按產品）

  • 概述
  • 動物纖維蛋白原濃縮物
  • 人類纖維蛋白原濃縮物

6. 全球纖維蛋白原濃縮物市場（依應用）

  • 概述
  • 先天性纖維蛋白原缺乏症
  • 手術程序

7. 全球纖維蛋白原濃縮物市場（按地區）

  • 概述
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 其他亞太地區
  • 世界其他地區
    • 拉丁美洲
    • 中東和非洲

8. 全球纖維蛋白原濃縮物市場競爭格局

  • 概述
  • 各公司市場排名
  • 主要發展策略

第9章 公司簡介

  • CSL Behring
  • LFB Group
  • ProFibix BV
  • Baxter International Inc.
  • Hualan Biological Engineering
  • Harbin Pacific Biopharmaceutical Co. Ltd
  • Green Cross Limited
  • Shanghai Xinxing Medicine Co. Ltd.
  • Green Cross Limited
  • Shanghai Xinxing Medicine Co. Ltd.

第10章 附錄

  • 相關調查
簡介目錄
Product Code: 54481

Fibrinogen Concentrates Market Size And Forecast

Fibrinogen Concentrates Market size was valued at USD 3.11 Billion in 2024 and is projected to reach USD 4.63 Billion by 2032, growing at a CAGR of 5.64% during the forecast period 2026-2032.

The Fibrinogen Concentrates Market is expected to show considerable growth owing to increasing blood-related disorders among people and growing acceptance of people for Fibrinogen Concentrate. The Global Fibrinogen Concentrates Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Fibrinogen Concentrates Market Definition

Fibrinogen is a glycoprotein present in the blood plasma and this is produced by the liver. Fibrinogen is present in the vertebrates which helps in the formation of a blood clot, sometimes blood clot is formed inside the blood vessels because of a low level of fibrinogen which leads to thrombosis and this interrupts the normal blood flow through the circulatory system. It is also helpful for making medicines for the disease-related blood. Thrombosis is an infrequent bleeding disorder that can be characterized by mild to critical forms of bleeding. The three forms of fibrinogen deficiency are hypofibrinogenemia, afibrinogenemia, and dysfibrinogenemia. When the patient is heavily bleeding the fibrinogen concentration enhances the whole blood clot rigidness and decreases the postoperative transfusion requirements.

Global Fibrinogen Concentrates Market Overview

In this competitive world, there is increasing stress among the people due to changes in their lifestyle as a result of this there is an increase in blood-related disorders, Congenital Fibrinogen is estimated to hold the largest share of this market which results in a better occurrence of hemophilia and better fibrinogen products. Increasing the use of fibrinogen concentrates for patients with the disease-related to bleeding such as congenital deficiencies is the primary factor driving the growth of this market. Nowadays people are more aware of their health and consider health their first priority is another important factor driving the growth of this market.

Presently, instead of traditional fibrinogen sources including frozen plasma or cryoprecipitate, Fibrinogen Concentrate is broadly being accepted by the people along with the firms. The Fibrinogen Concentrates Market is increasing due to the growing patient population and use of various surgical procedures which has led to the increased demand for Fibrinogen. Moreover, The Fibrinogen concentrates are being utilized to prepare anti-coagulates which are used in the treatment of congenital afibrinogenemia, dysfibrinogenemia, hypofibrinogenemia, and others.

Global Fibrinogen Concentrates Market: Segmentation Analysis

The Global Fibrinogen Concentrates Market is Segmented on the basis of Product, Application, and Geography.

Fibrinogen Concentrates Market, By Product

  • Animal Fibrinogen Concentrates
  • Human Fibrinogen Concentrates

Based on Product, the market is segmented into Animal Fibrinogen Concentrates and Human Fibrinogen Concentrate. Human Fibrinogen Concentrate is estimated to hold the largest share of this segment during the forecasted period due to the increasing requirement for fibrinogen concentrate to treat bleeding disorders and congenital coagulation deficiencies.

Fibrinogen Concentrates Market, By Application

  • Congenital Fibrinogen Deficiency
  • Surgical Procedures
  • ased on Application, the market is segmented into Congenital Fibrinogen Deficiency and Surgical Procedures. Congenital Fibrinogen is estimated to show the highest growth during the forecasted period owing to high incidences of hemophilia and increasing bleeding disorders among people. The safety proven by fibrinogen concentrates and advancements in fibrinogen products has also led to the growth of this segment in the Fibrinogen Concentrates Market.

Fibrinogen Concentrates Market, By Geography

  • North America
  • Europe
  • Asia Pacific
  • Rest of the world
  • On the basis of regional analysis, the Global Fibrinogen Concentrates Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. North America is estimated to hold the largest share of this market because of the increasing burden of bleeding disorders and growing geriatric population and acquired hemophilia which is a rare autoimmune disorder is foremost in the geriatric population and a disease called Von Willebrand is one of the most common bleeding disorder which affects almost 1% of the population every year in the United States. These are the major factors contributing to the growth of the Fibrinogen Concentrates Market in this region.

Key Players

The "Global Fibrinogen Concentrates Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are CSL Behring, LFB Group, ProFibix BV, Baxter International Inc., Hualan Biological Engineering, Harbin Pacific Biopharmaceutical Co. Ltd, Green Cross Limited, and Shanghai Xinxing Medicine Co. Ltd. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Key Developments

  • December 2021 - LFB plasma which is a part of LFB Group announced its acquisition of Immuno Tek Bio Centre in Florence, South California. LFB Group is a global biopharmaceutical company that develops and provides plasma-derived and recombinant products through its innovative technologies.
  • January 2022 - GC Cell and Rivaara Immune Private Limited announced that they are about to enter into an exclusive licensing agreement, Rivaara Immune has agreed to develop and commercialize Immunecell-LC.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL FIBRINOGEN CONCENTRATES MARKET

  • 1.1 Overview of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 3.1 Data Mining
  • 3.2 Validation
  • 3.3 Primary Interviews
  • 3.4 List of Data Sources

4 GLOBAL FIBRINOGEN CONCENTRATES MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porters Five Force Model
  • 4.4 Value Chain Analysis

5 GLOBAL FIBRINOGEN CONCENTRATES MARKET, BY PRODUCT

  • 5.1 Overview
  • 5.2 Animal Fibrinogen Concentrate
  • 5.3 Human Fibrinogen Concentrate

6 GLOBAL FIBRINOGEN CONCENTRATES MARKET, BY APPLICATION

  • 6.1 Overview
  • 6.2 Congenital Fibrinogen Deficiency
  • 6.3 Surgical Procedures

7 GLOBAL FIBRINOGEN CONCENTRATES MARKET, BY GEOGRAPHY

  • 7.1 Overview
  • 7.2 North America
    • 7.2.1 U.S.
    • 7.2.2 Canada
    • 7.2.3 Mexico
  • 7.3 Europe
    • 7.3.1 Germany
    • 7.3.2 U.K.
    • 7.3.3 France
    • 7.3.4 Rest of Europe
  • 7.4 Asia Pacific
    • 7.4.1 China
    • 7.4.2 Japan
    • 7.4.3 India
    • 7.4.4 Rest of Asia Pacific
  • 7.5 Rest of the World
    • 7.5.1 Latin America
    • 7.5.2 Middle East & Africa

8 GLOBAL FIBRINOGEN CONCENTRATES MARKET, BY COMPETITIVE LANDSCAPE

  • 8.1 Overview
  • 8.2 Company Market Ranking
  • 8.3 Key Development Strategies

9 COMPANY PROFILES

  • 9.1 CSL Behring
    • 9.1.1 Overview
    • 9.1.2 Financial Performance
    • 9.1.3 Product Outlook
    • 9.1.4 Key Developments
  • 9.2 LFB Group
    • 9.2.1 Overview
    • 9.2.2 Financial Performance
    • 9.2.3 Product Outlook
    • 9.2.4 Key Developments
  • 9.3 ProFibix BV
    • 9.3.1 Overview
    • 9.3.2 Financial Performance
    • 9.3.3 Product Outlook
    • 9.3.4 Key Developments
  • 9.4 Baxter International Inc.
    • 9.4.1 Overview
    • 9.4.2 Financial Performance
    • 9.4.3 Product Outlook
    • 9.4.4 Key Developments
  • 9.5 Hualan Biological Engineering
    • 9.5.1 Overview
    • 9.5.2 Financial Performance
    • 9.5.3 Product Outlook
    • 9.5.4 Key Developments
  • 9.6 Harbin Pacific Biopharmaceutical Co. Ltd
    • 9.6.1 Overview
    • 9.6.2 Financial Performance
    • 9.6.3 Product Outlook
    • 9.6.4 Key Developments
  • 9.7 Green Cross Limited
    • 9.7.1 Overview
    • 9.7.2 Financial Performance
    • 9.7.3 Product Outlook
    • 9.7.4 Key Developments
  • 9.8 Shanghai Xinxing Medicine Co. Ltd.
    • 9.8.1 Overview
    • 9.8.2 Financial Performance
    • 9.8.3 Product Outlook
    • 9.8.4 Key Developments
  • 9.9 Green Cross Limited
    • 9.9.1 Overview
    • 9.9.2 Financial Performance
    • 9.9.3 Product Outlook
    • 9.9.4 Key Developments
  • 9.10 Shanghai Xinxing Medicine Co. Ltd.
    • 9.10.1 Overview
    • 9.10.2 Financial Performance
    • 9.10.3 Product Outlook
    • 9.10.4 Key Developments

10 Appendix

  • 10.1 Related Research